Printer Friendly

James Cardia to Manage Business Development and Partnering at RXi Pharmaceuticals with Departure of Chief Business Officer Eliseev.

M2 PHARMA-September 18, 2017-James Cardia to Manage Business Development and Partnering at RXi Pharmaceuticals with Departure of Chief Business Officer Eliseev

(C)2017 M2 COMMUNICATIONS

- Effective immediately, Dr. Alexey Eliseev, chief business officer of US-based clinical-stage RNAi company RXi Pharmaceuticals Corp. (NASDAQ: RXII), will depart the company, the company said.

Eliseev, former CEO of MirImmune Inc., joined RXi on January 6, 2017 as chief business officer in connection with the company's acquisition of MirImmune, a privately-held company developing cell-based therapeutics for cancer treatments based on a license to RXi's proprietary self-delivering RNAi technology.

In his role as chief business officer of RXi, Eliseev was responsible for the integration of this new therapeutic approach into the activities of RXi Pharmaceuticals, and for introducing the company to several key industry and academic groups active in this emerging field.

Dr. James Cardia, RXi's current director of business development and intellectual property will take over the management of the various ongoing activities in partnering and business development.

During his tenure at RXi, Cardia's group has been responsible for the discovery and optimisation of "self-delivering" rxRNAs (sd-rxRNAs) as well as the development and characterisation of RXI-109, an anti-fibrotic agent currently in clinical trials for the treatment of both dermal and retinal scarring.

He has participated in multiple out-licensing, in-licensing and acquisition deals and has contributed to numerous publications and patent applications.

Cardia has a Ph.D. in chemistry from Boston College and received postdoctoral training in the Department of Chemistry and Chemical Biology at Harvard University.

RXi Pharmaceuticals develops innovative therapeutics that address significant unmet medical needs.

Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition.

The company has developed a robust RNAi therapeutic platform, including self-delivering RNA (sd-rxRNA) compounds, that have the ability to selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas.

Current programmes include dermatology, ophthalmology, and cell-based cancer immunotherapy.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 18, 2017
Words:357
Previous Article:Bristol-Myers Squibb names new director.
Next Article:Former President and CEO of Incyte Joins Alexion Board of Directors.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters